Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Announces First Patient Dosed in China Trial of TROP2 ADC

publication date: Dec 3, 2020

Shanghai Junshi Bio reported the first patient has been dosed in a China Phase I trial of its anti-TROP2-Tub196 antibody drug conjugate. Junshi says TROP2 is a receptor expressed at high levels in several solid tumor cancers (including breast, gastric, NSCLC, SCLC, colon and pancreatic). Over-expression of TROP2 is correlated with poor prognosis clinically. In 2018, Junshi's Tuoyi (toripalimab) was the first China-developed anti-PD-1 mAb approved for China use. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.